Top-Rated StocksTop-RatedNASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $76.08 +2.43 (+3.30%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$76.08 0.00 (0.00%) As of 08/22/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvalent Stock (NASDAQ:NUVL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvalent alerts:Sign Up Key Stats Today's Range$73.68▼$76.4450-Day Range$72.16▼$85.6952-Week Range$55.53▼$113.51Volume407,091 shsAverage Volume509,960 shsMarket Capitalization$5.49 billionP/E RatioN/ADividend YieldN/APrice Target$118.91Consensus RatingBuy Company Overview Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Read More Nuvalent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNUVL MarketRank™: Nuvalent scored higher than 66% of companies evaluated by MarketBeat, and ranked 371st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingNuvalent has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvalent has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvalent's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($3.86) to ($4.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -15.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -15.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvalent's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.99% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently decreased by 2.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.99% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently decreased by 2.37%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment0.99 News SentimentNuvalent has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Nuvalent this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,455,872.00 in company stock.Percentage Held by Insiders10.20% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVL Stock News HeadlinesInsider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of StockAugust 20 at 5:26 AM | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 SharesAugust 9, 2025 | insidertrades.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.August 23 at 2:00 AM | Weiss Ratings (Ad)Piper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)August 20 at 2:17 AM | americanbankingnews.comPiper Sandler Initiates Coverage of Nuvalent (NUVL) with Overweight RecommendationAugust 19, 2025 | msn.comNuvalent initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comNuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential SymposiumAugust 13, 2025 | prnewswire.comNuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prnewswire.comSee More Headlines NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $78.28 at the start of the year. Since then, NUVL stock has decreased by 2.8% and is now trading at $76.08. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by $0.04. When did Nuvalent IPO? Nuvalent (NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Top institutional investors of Nuvalent include State Street Corp (2.08%), Perceptive Advisors LLC (1.92%), Commodore Capital LP (1.91%) and Braidwell LP (1.64%). Insiders that own company stock include Andrew A F Hack, James Richard Porter, Matthew Shair, Alexandra Balcom, Henry E Pelish, Deborah Ann Miller, Darlene Noci, Christopher Durant Turner and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvalent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/07/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Nuvalent$118.91 High Price Target$140.00 Low Price Target$100.00 Potential Upside/Downside+56.3%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$260.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.58% Return on Assets-30.14% Debt Debt-to-Equity RatioN/A Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.03 per share Price / Book5.84Miscellaneous Outstanding Shares72,110,000Free Float64,750,000Market Cap$5.49 billion OptionableOptionable Beta1.30 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NUVL) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.